Affiliation:
1. Russian Medical Academy for Postgraduate Continuous Education
2. Central Clinical Hospital ‘Russian Railways – Medicine’
3. Moscow State University of Medicine and Dentistry n.a. A.I. Evdokimov
Abstract
Arterial hypertension (AH) remains one of the most significant medical and social problems in the world, its prevalence among the adult population is 30–45%. Along with this, the modern population is characterized by a high incidence of chronic kidney disease (CKD), including due to their secondary damage in the framework of hypertension. In turn, CKD is an important independent risk factor for the development and progression of cardiovascular diseases, including fatal ones. The use of existing approaches to nephroprotection in the treatment of patients with hypertension will significantly improve the prognosis both in patients with risk factors for developing renal dysfunction and in patients with pre-existing kidney disease. According to current recommendations for hypertension in such clinical situations, therapy should begin with fixed combinations of antihypertensive drugs. The combination of an angiotensin converting enzyme inhibitor (ACE) and a dihydropyridine calcium channel blocker (CCВ) demonstrated the greatest effectiveness according to evidence-based medicine in patients with high-risk hypertension, including from the standpoint of nephroprotection. In the presented clinical case, the successful use of a fixed combination of ACE and CCВ in a patient with hypertension and microalbuminuria is described.
Subject
Materials Chemistry,Economics and Econometrics,Media Technology,Forestry
Reference62 articles.
1. Muromtseva G. A., Kontsevaya A. V., Konstantinov V. V., Artamonova G. V., Gatagonova T. M., Duplyakov D. V. et al. The prevalence of non-infectious diseases risk factors in Russian population in 2012–2013 years. The results of ECVD-RF. Cardiovascular Therapy and Prevention. 2014; 13 (6): 4–11. http://dx.doi. org/10.15829/1728–8800–2014–6–4–11.
2. Boytsov S.A., Balanova Y.A., Shalnova S.A., Deev A.D., Artamonova G.V., Gatagonova T.M. et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. By the data from eccd. Cardiovascular Therapy and Prevention. 2014; 13 (4): 4–14. https://doi.org/10.15829/1728–8800–2014–4–4–14.
3. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005; 365: 217–223. DOI: 10.1016/S0140–6736(05)17741–1.
4. Franklin SS, Lopez VA, Wong ND, Mitchell GF, Larson MG, Vasan RS et al. Single versus combined blood pressure components and risk for cardiovascular disease: the Framingham Heart Study. Circulation. 2009; 119: 243–250. https://doi. org/10.1007/978–1–4471–5198–2_20.
5. Williams B, Mancia G, Spiering W Rosei AA, Azizi M, Burnier M, et al. 2018. ESC/ ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018; 36 (10): 1953–2041. DOI: 10.1097/HJH.0000000000002017.